VSTM News & Events

"2025 was a transformative year for Verastem Oncology and the patients we serve. We transitioned to a commercial-stage company with the launch of AVMAPKI FAKZYNJA CO-PACK, the first treatment specifically approved by the FDA for KRAS-mutated recurrent low-grade serous ovarian cancer. We also advanced multiple clinical programs across several RAS/MAPK pathway-driven solid tumor cancers," said Dan Paterson, president and chief executive officer at Verastem Oncology. "In 2026, we are well-positioned to drive sustainable growth with our successful commercial launch and to accelerate our clinical path for VS-7375, our potential best-in-class oral KRAS G12D inhibitor, with several important data readouts and preparations for potential registration-directed clinical trials."

Equity futures were little changed after the close following a broad selloff as the markets approach the end of the calendar year. Traders are wrestling with profit-taking in major tech and AI-linked names even as the broader benchmark indexes remain close to all-time peaks.HIGHER AFTER EARNINGS -Cemtrexup 33.2%ALSO HIGHER -Ekso Bionicsup 42.9% after agreeing to combine with Applied Digital'scloud computing businessFly-E Groupup 54.2% after regaining compliance with Nasdaq listing rulesTEN Holdingsup 19.1% after announcing a $2.25M private placement of common stockLOWER -Verastemdown 3.1% after discontinuing its RAMP 203 clinical trial